Chemical Compound Review:
Deprenil N-methyl-N-(1-phenylpropan-2- yl)prop-2-yn...
Synonyms:
CHEBI:50217, CHEBI:118032, AR-1L0637, LS-103418, LS-171873, ...
Kalász,
Bartók,
Szöko,
Haberle,
Kiss,
Hennings,
Magyar,
Fürst,
Keller,
Huang,
Dimayuga,
Maragos,
Anttila,
Sotaniemi,
Pelkonen,
Rautio,
Salonen,
Nyman,
Boobis,
Edwards,
Watts,
Lake,
Price,
Renwick,
Gómez-Lechón,
Castell,
Ingelman-Sundberg,
Hidestrand,
Guillouzo,
Corcos,
Goldfarb,
Lewis,
Taavitsainen,
Pelkonen,
Shoulson,
Oakes,
Fahn,
Lang,
Langston,
LeWitt,
Olanow,
Penney,
Tanner,
Kieburtz,
Rudolph,
Magyar,
Pálfi,
Tábi,
Kalász,
Szende,
Szöko,
- The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Tetrud, J.W., Langston, J.W. Science (1989)
- Possible mechanism of action of deprenyl in parkinsonism. Paterson, I.A., Juorio, A.V., Boulton, A.A. Lancet (1990)
- Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Shoulson, I., Oakes, D., Fahn, S., Lang, A., Langston, J.W., LeWitt, P., Olanow, C.W., Penney, J.B., Tanner, C., Kieburtz, K., Rudolph, A. Ann. Neurol. (2002)
- Dopamine induces proteasome inhibition in neural PC12 cell line. Keller, J.N., Huang, F.F., Dimayuga, E.R., Maragos, W.F. Free Radic. Biol. Med. (2000)
- Pharmacological aspects of (-)-deprenyl. Magyar, K., Pálfi, M., Tábi, T., Kalász, H., Szende, B., Szöko, E. Current medicinal chemistry. (2004)
- A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Sano, M., Ernesto, C., Thomas, R.G., Klauber, M.R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C.W., Pfeiffer, E., Schneider, L.S., Thal, L.J. N. Engl. J. Med. (1997)
- Deprenyl in narcolepsy. Schachter, M., Price, P.A., Perkes, J.D. Lancet (1979)
- A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Feigin, A., Kurlan, R., McDermott, M.P., Beach, J., Dimitsopulos, T., Brower, C.A., Chapieski, L., Trinidad, K., Como, P., Jankovic, J. Neurology (1996)
- A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. George, T.P., Vessicchio, J.C., Termine, A., Jatlow, P.I., Kosten, T.R., O'Malley, S.S. Biol. Psychiatry (2003)
- Selegiline in the treatment of narcolepsy. Hublin, C., Partinen, M., Heinonen, E.H., Puukka, P., Salmi, T. Neurology (1994)
- Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Fowler, J.S., MacGregor, R.R., Wolf, A.P., Arnett, C.D., Dewey, S.L., Schlyer, D., Christman, D., Logan, J., Smith, M., Sachs, H. Science (1987)
- Monoamine oxidase: an important intracellular regulator of gastrin release in the rat. Dial, E.J., Huang, J., Delansorne, R., Lichtenberger, L.M. Gastroenterology (1986)
- Oxidative stress and antioxidant therapy in Parkinson's disease. Ebadi, M., Srinivasan, S.K., Baxi, M.D. Prog. Neurobiol. (1996)
- DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Shoulson, I. Ann. Neurol. (1998)
- Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease. Kushleika, J., Checkoway, H., Woods, J.S., Moon, J.D., Smith-Weller, T., Franklin, G.M., Swanson, P.D. Ann. Neurol. (1996)
- MPTP, selegiline, and parkinsonism. Akos, K. Lancet (1987)
- Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Richard, I.H., Kurlan, R., Tanner, C., Factor, S., Hubble, J., Suchowersky, O., Waters, C. Neurology (1997)
- The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia. Sachdev, P., Saharov, T., Cathcart, S. Biol. Psychiatry (1999)
- Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonism. Shults, C.W., Nasirian, F., Ward, D.M., Nakano, K., Pay, M., Hill, L.R., Haas, R.H. Neurology (1995)
- Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro. Khaldy, H., Escames, G., León, J., Vives, F., Luna, J.D., Acuña-Castroviejo, D. J. Pineal Res. (2000)
- Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. Saura, J., Kettler, R., Da Prada, M., Richards, J.G. J. Neurosci. (1992)
- Marked effect of liver and kidney function on the pharmacokinetics of selegiline. Anttila, M., Sotaniemi, E.A., Pelkonen, O., Rautio, A. Clin. Pharmacol. Ther. (2005)
- (-)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Paterson, I.A., Barber, A.J., Gelowitz, D.L., Voll, C. Neuroscience and biobehavioral reviews. (1997)
- Pharmacology of selegiline. Gerlach, M., Youdim, M.B., Riederer, P. Neurology (1996)
- Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease. Turkka, J., Suominen, K., Tolonen, U., Sotaniemi, K., Myllylä, V.V. Neurology (1997)
- Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Heinonen, E.H., Anttila, M.I., Lammintausta, R.A. Clin. Pharmacol. Ther. (1994)
- Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Rinne, J.O., Röyttä, M., Paljärvi, L., Rummukainen, J., Rinne, U.K. Neurology (1991)
- Chronic inhibition of the high-affinity dopamine uptake system increases oxidative damage to proteins in the aged rat substantia nigra. Romero-Ramos, M., Rodríguez-Gómez, J.A., Venero, J.L., Cano, J., Machado, A. Free Radic. Biol. Med. (1997)
- Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl. Andoh, T., Chock, P.B., Murphy, D.L., Chiueh, C.C. Mol. Pharmacol. (2005)
- CYP2D6 polymorphism is not crucial for the disposition of selegiline. Scheinin, H., Anttila, M., Dahl, M.L., Karnani, H., Nyman, L., Taavitsainen, P., Pelkonen, O., Bertilsson, L. Clin. Pharmacol. Ther. (1998)
- Analysis of deprenyl metabolites in the rat brain using HPLC-ES-MS. Kalász, H., Bartók, T., Szöko, E., Haberle, D., Kiss, J.P., Hennings, E.C., Magyar, K., Fürst, S. Current medicinal chemistry. (1999)
- Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Schulz, R., Antonin, K.H., Hoffmann, E., Jedrychowski, M., Nilsson, E., Schick, C., Bieck, P.R. Clin. Pharmacol. Ther. (1989)
- Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. Lamensdorf, I., Youdim, M.B., Finberg, J.P. J. Neurochem. (1996)
- Assessment of the N-oxidation of deprenyl, methamphetamine, and amphetamine enantiomers by chiral capillary electrophoresis: an in vitro metabolism study. Szöko, E., Tábi, T., Borbás, T., Dalmadi, B., Tihanyi, K., Magyar, K. Electrophoresis (2004)
- Rapid and simultaneous determination of monoamine oxidase A and monoamine oxidase B activities in mouse brain homogenates by liquid chromatography with electrochemical detection. Freeman, K.B., Bulawa, M.C., Zeng, Q., Blank, C.L. Anal. Biochem. (1993)
- Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Salonen, J.S., Nyman, L., Boobis, A.R., Edwards, R.J., Watts, P., Lake, B.G., Price, R.J., Renwick, A.B., Gómez-Lechón, M.J., Castell, J.V., Ingelman-Sundberg, M., Hidestrand, M., Guillouzo, A., Corcos, L., Goldfarb, P.S., Lewis, D.F., Taavitsainen, P., Pelkonen, O. Drug Metab. Dispos. (2003)
- Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys. Winger, G.D., Yasar, S., Negus, S.S., Goldberg, S.R. Clin. Pharmacol. Ther. (1994)
- Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Baronti, F., Davis, T.L., Boldry, R.C., Mouradian, M.M., Chase, T.N. Neurology (1992)
- Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Pålhagen, S., Heinonen, E.H., Hägglund, J., Kaugesaar, T., Kontants, H., Mäki-Ikola, O., Palm, R., Turunen, J. Neurology (1998)
- Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Wecker, L., James, S., Copeland, N., Pacheco, M.A. Biol. Psychiatry (2003)
- Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Olanow, C.W., Myllylä, V.V., Sotaniemi, K.A., Larsen, J.P., Pålhagen, S., Przuntek, H., Heinonen, E.H., Kilkku, O., Lammintausta, R., Mäki-Ikola, O., Rinne, U.K. Neurology (1998)